Type 2 diabetes is associated with higher risk of pancreatic, liver, endometrial, colorectal, breast, bladder, and kidney cancers, and lower risk of prostate cancer. Insulin resistance, hyperinsulinemia, chronic inflammation, and obesity link diabetes to cancer biology. Metformin has been associated with lower cancer risk in observational studies.
How Diabetes Promotes Cancer
- Hyperinsulinemia — chronically elevated insulin acts as a growth factor and amplifies insulin-like growth factor 1 (IGF-1) signaling
- IGF-1 signaling — promotes cell proliferation and survival, particularly in epithelial cancers
- Hyperglycemia — provides fuel for rapidly dividing cancer cells (Warburg effect); promotes oxidative stress and DNA damage
- Chronic low-grade inflammation — elevated IL-6, TNF-alpha, and CRP create a tumor-promoting microenvironment
- Obesity — adipose tissue produces estrogens, leptin, adiponectin abnormalities, and free fatty acids that drive cancer biology
- Altered immune surveillance — diabetes may reduce immune detection of early tumor cells
- Microbiome changes — diabetes and obesity alter gut microbiota in ways that may promote colorectal cancer
Cancers With Higher Risk in Type 2 Diabetes
| Cancer | Relative Risk | Notes |
|---|---|---|
| Pancreatic | 1.8 to 2 fold | Strongest known relationship; new-onset diabetes after 50 with weight loss can be early sign |
| Liver (hepatocellular carcinoma) | 2 to 3 fold | Largely mediated by NAFLD/NASH progression |
| Endometrial | About 2 fold | Insulin resistance, hyperestrogenism, PCOS often coexist |
| Colorectal | 1.2 to 1.4 fold | Shared lifestyle factors plus hyperinsulinemia |
| Bladder | 1.2 to 1.5 fold | Particularly in men; possible role of glycosuria and infection |
| Kidney | 1.4 fold | Linked to obesity, hypertension, and CKD |
| Postmenopausal breast | 1.1 to 1.2 fold | Obesity-mediated estrogen production |
| Non-Hodgkin lymphoma | 1.2 fold | Modest signal |
| Gallbladder | 1.5 to 1.6 fold | Shared with obesity and gallstone disease |
Cancers With Lower Risk in Type 2 Diabetes
- Prostate cancer — relative risk about 0.7 to 0.9
- Possible explanations include lower testosterone, altered IGF-1, lower PSA from obesity-related hemodilution, and differences in screening uptake
- This is paradoxical given other epithelial cancers are higher; biology not fully understood
- Premenopausal breast cancer also shows no clear increase or possibly slight decrease
Type 1 Diabetes and Cancer
- Less data available than for type 2 diabetes
- Modest increases observed for stomach, cervical, and possibly ovarian cancer
- Different mechanism — autoimmune background may predispose to certain cancers
- Hyperinsulinemia-driven cancers (liver, pancreatic) are less of a concern in type 1 (which has insulin deficiency)
- Long-duration type 1 diabetes with poor control may share some risks with type 2
Metformin and Cancer
- Multiple meta-analyses of observational studies show 20% to 40% lower cancer incidence in metformin users vs other diabetes drugs
- Largest signals for liver, pancreatic, and colorectal cancer
- Mortality benefit also observed in metformin users with several existing cancers
- Proposed mechanisms — reduced circulating insulin, AMPK activation, mTOR inhibition, direct anti-proliferative effects, gut microbiome modulation
- Randomized trial data limited; most evidence is observational and subject to time-related bias
- Several adjuvant cancer trials with metformin underway
- Not currently recommended specifically for cancer prevention but continued use is reassuring
Other Diabetes Drugs and Cancer Signals
- Insulin and insulin analogues — early concerns about glargine and breast cancer were not confirmed in subsequent large studies and randomized data
- Pioglitazone — possible small increase in bladder cancer; weighed against cardiovascular benefit
- SGLT2 inhibitors — generally neutral on cancer risk
- GLP-1 receptor agonists — early animal data raised C-cell thyroid concerns; human surveillance has not shown clear increase; weight loss may reduce some obesity-related cancer risks
- Sulfonylureas — mostly neutral; some studies suggest higher cancer rates than metformin (likely reflecting metformin’s protective effect rather than sulfonylurea harm)
Cancer Treatments and Glycemic Control
| Treatment | Effect on Glucose | Management |
|---|---|---|
| Corticosteroids (prednisone, dexamethasone) | Significant hyperglycemia, especially afternoon and evening | Insulin often needed; mid-day dosing matters |
| L-asparaginase | Hyperglycemia, ketoacidosis possible | Close monitoring; insulin if needed |
| Mammalian target of rapamycin inhibitors (everolimus) | Hyperglycemia common | Insulin or other diabetes drugs |
| Androgen-deprivation therapy | Insulin resistance, weight gain | Lifestyle plus medication adjustment |
| Immune checkpoint inhibitors | Autoimmune diabetes (rare) | Insulin immediately; permanent in most cases |
| Tyrosine kinase inhibitors | Variable effects | Monitor and adjust |
| Total parenteral nutrition | Hyperglycemia from dextrose load | Insulin in TPN |
| Pancreatectomy | Type 3c (pancreatogenic) diabetes | Insulin and pancreatic enzyme replacement |
Recognizing Cancer Symptoms in Diabetes
- Unintentional weight loss — never assume it is from improved diabetes; rule out pancreatic, GI, or hematologic malignancy
- New abdominal pain or jaundice — possible pancreatic or liver malignancy
- Blood in stool or change in bowel habits — colonoscopy indicated
- Blood in urine — bladder or kidney cancer workup
- Postmenopausal bleeding — endometrial cancer until proven otherwise
- New breast lump — diagnostic imaging
- Persistent cough, hemoptysis, hoarseness — lung cancer in smokers
- Sudden hard-to-control hyperglycemia in older adults — consider new-onset cancer, especially pancreatic
Cancer Screening Recommendations
Standard age- and sex-based recommendations apply. Key items:
- Colorectal — colonoscopy every 10 years from age 45 to 75 (or alternative stool-based tests)
- Breast — mammography every 1 to 2 years from age 40 or 50 (depending on guideline) through 74
- Cervical — Pap and/or HPV testing every 3 to 5 years for ages 25 to 65
- Lung — low-dose CT for current and former smokers aged 50 to 80 with 20+ pack-year history
- Prostate — discuss PSA screening starting age 50 (45 if Black or family history)
- Skin — periodic full-body skin examination for those with risk factors
- Liver — ultrasound and AFP every 6 months for people with cirrhosis
- Pancreatic — no routine screening for general population; surveillance for high-risk groups (BRCA, Lynch, FAMMM, strong family history)
For a closer look at screening, see our piece on diabetes cancer screening.
Lifestyle Strategies That Lower Cancer Risk
- Maintain healthy weight — body fat is causally linked to at least 13 cancers
- Regular physical activity — 150 to 300 minutes per week moderate or 75 to 150 minutes vigorous
- Mediterranean or plant-forward diet — high in vegetables, fruits, whole grains, legumes, nuts, fish
- Limit red and processed meat — particularly for colorectal cancer prevention
- Alcohol — minimize; alcohol is a known carcinogen for several cancers
- Don’t smoke — smoking causes at least 15 cancers
- Sun protection — reduces skin cancer risk
- Vaccination — HPV vaccine and hepatitis B vaccine prevent cancer-causing infections
- Optimize diabetes control — sustained good glycemic control may reduce some cancer risks
See diet and nutrition for diet patterns. For background on shared mechanisms, see our pieces on NAFLD and diabetes (a major route to liver cancer) and pancreatic cancer and diabetes.
Cancer Care When You Have Diabetes
- Plan diabetes management ahead of cancer treatment — anticipate steroid bursts, chemo cycles, surgery
- Continuous glucose monitoring often helpful during treatment
- Coordinate among oncologist, endocrinologist, and primary care
- Watch for opportunistic infections — hyperglycemia and immunosuppression compound
- Nutrition support — cancer cachexia and diabetes management can conflict
- Cardiovascular vigilance — many cancer treatments are cardiotoxic and add to existing diabetes-related risk
- Bone health — some cancer treatments accelerate osteoporosis, already a risk in diabetes
When to Seek Care
- Unintentional weight loss of 5% or more in 6 months without explanation
- New or worsening abdominal pain
- Jaundice (yellow skin or eyes)
- Blood in stool, urine, or sputum
- New lumps or persistent skin changes
- Postmenopausal bleeding
- Sudden hard-to-control glucose changes without obvious cause, especially after age 50
- Persistent unexplained fatigue, fever, or night sweats
Related Reading
For related complications, see pancreatic cancer and diabetes, diabetes cancer screening, NAFLD and diabetes, and the complications hub. For dietary detail, see diet and nutrition. For background on diabetes and cancer mechanisms, see the ADA/ACS consensus report on diabetes and cancer.
The Bottom Line
Type 2 diabetes raises risk for several cancers — pancreatic, liver, endometrial, colorectal, bladder, kidney, and postmenopausal breast — through hyperinsulinemia, hyperglycemia, chronic inflammation, and obesity. Prostate cancer risk is paradoxically lower. Metformin use has been linked to modestly reduced cancer incidence and mortality, though randomized confirmation is limited. Cancer-directed treatments often disrupt glycemic control and require coordinated diabetes management. Standard age- and sex-based screening applies, with extra attention to symptoms that could signal increased-risk cancers. Lifestyle prevention overlaps substantially with diabetes care — maintaining healthy weight, exercising regularly, eating a plant-forward diet, minimizing alcohol, and not smoking address both conditions at once.
